September 11, 2015 (Shareholders Foundation) - An investigation on behalf of investors of Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) shares over potential securities laws violations by Tetraphase Pharmaceuticals and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) concerning whether a series of statements by Tetraphase Pharmaceuticals regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Tetraphase Pharmaceuticals Inc reported that its annual Total Revenue declined from $10.49 million in 2013 to $9.10 million in 2014 and that its respective Net Loss increased from $29.64 million to $66.74 million. Shares of Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) grew from $8.83 per share in May 2014 to as high as $51.75 per share in July 2015.

On September 8, 2015, Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) announced that the IGNITE2 phase 3 clinical trial of eravacycline administered as an IV to oral transition therapy for the treatment of complicated urinary tract infections (cUTI) did not achieve its primary endpoint of statistical non-inferiority compared to levofloxacin. Shares of Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) declined to as low as $9.06 per share on September 9, 2015.